Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 8;19(1):179.
doi: 10.3390/ijms19010179.

Scanning the Immunopathogenesis of Psoriasis

Andrea Chiricozzi  1 , Paolo Romanelli  2 , Elisabetta Volpe  3 , Giovanna Borsellino  4 , Marco Romanelli  5
Affiliations
Review

Scanning the Immunopathogenesis of Psoriasis

Andrea Chiricozzi et al. Int J Mol Sci. .

Abstract

Psoriasis is a chronic inflammatory skin disease, the immunologic model of which has been profoundly revised following recent advances in the understanding of its pathophysiology. In the current model, a crosstalk between keratinocytes, neutrophils, mast cells, T cells, and dendritic cells is thought to create inflammatory and pro-proliferative circuits mediated by chemokines and cytokines. Various triggers, including recently identified autoantigens, Toll-like receptor agonists, chemerin, and thymic stromal lymphopoietin may activate the pathogenic cascade resulting in enhanced production of pro-inflammatory and proliferation-inducing mediators such as interleukin (IL)-17, tumor necrosis factor (TNF)-α, IL-23, IL-22, interferon (IFN)-α, and IFN-γ by immune cells. Among these key cytokines lie therapeutic targets for currently approved antipsoriatic therapies. This review aims to provide a comprehensive overview on the immune-mediated mechanisms characterizing the current pathogenic model of psoriasis.

Keywords: IL-17; IL-23; autoantigen; autoreactive T cells; chemokines; cytokines; dendritic cells; immunology; pathogenesis; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The pathogenic model based on the IL-23/IL-17 axis inducing the development of psoriatic phenotype. Multiple factors induce mDCs activation with consequent IL-23 production (IFN-α, TSLP), that, in turn, stimulates mainly T cell subsets, but also ILC3, mast cells, and neutrophils, to secrete IL-17. Other cytokines derived from T cells, mast cells, and ILC3 (IL-22, IL-17F, and IL-21), and from mDCs (TNFα, NO, and IL-20) contribute to the development of psoriatic skin. Autoantigens involved in this pathway are highlighted in yellow. T17 and T22 cells represent all T cell subsets producing mainly IL-17 and IL-22, respectively. The IL-23/IL17 axis, the main immune pathway in psoriasis pathogenesis, is highlighted in red, while the other immune signals are designed in blue. CCL: CC chemokine ligands; CXCL: chemokine (C-X-C motif) ligand; ADAMTSL5: Thrombospondin Type 1 motif-like 5; β-DEF: β-defenins; IFN: interferon; IL: interleukin; KC: keratinocyte; mDC: myeloid Dendritic Cell; NKT: Natural Killer T cell; NO: nitric oxide; pDC: plasmacytoid Dendritic Cells; TNF: tumor necrosis factor; TSLP: Thymic stromal lymphopoietin.
Figure 2
Figure 2
Therapeutic “hierarchy” of pathogenic cytokines in psoriasis. (A) The shooting target shows the best targets for treatment of psoriasis (IL-17, IL-23, and TNF-α). Moving away from the center, other pathogenic cytokines have proved to be less therapeutically relevant because their blockade resulted in a poor clinical response [11,128,129,130,131,132]; (B) key-cytokines (IFNα, TNFα, IL-23, and IL-17) in upstream and downstream points within the psoriatic inflammatory cascade, and other relevant contributors: IFN-γ, IL-22, IL-1F9, IL-8, and CCL20. CCL: CC chemokine ligands; IFN: interferon; IL: interleukin; TNF: tumor necrosis factor.
Figure 3
Figure 3
Feed-forward inflammatory circuits involving keratinocytes. IL-17 auto-amplifies its signal through the stimulation of keratinocytes which then produce CCL20 (A) or other chemoattractans (B) recruiting IL-17-producing T cells (A) and other inflammatory cells. In a similar auto-sustaining manner, IFN-γ-secreting T cells are recruited through keratinocyte production of chemokines (CXCL9-11) induced by IFN-γ (C). CCL: CC chemokine ligands; CCR: C-C chemokine receptor; CXCL: chemokine (C-X-C motif) ligand; CXCR: C-X-C motif chemokine receptor; IFN: interferon; IL: interleukin; KC: keratinocyte; Th: T helper; Tc: T cytotoxic; TNF: tumor necrosis factor.
Figure 4
Figure 4
Activation of pDCs. Self-nucleic acids (both DNA and RNA) derived from damaged cells when complexed with AMPs, including LL37, and Th17-derived cytokine IL-26, can activate pDCs through TLR activation. pDCs migration and activation can be also induced by chemerin, an inflammatory protein mainly secreted by fibroblasts. pDCs: plasmacytoid Dendritic Cells; TLR: Toll-like Receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gottlieb S.L., Gilleaudeau P., Johnson R., Estes L., Woodworth T.G., Gottlieb A.B., Krueger J.G. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggest a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1995;1:442–447. doi: 10.1038/nm0595-442. - DOI - PubMed
    1. Valdimarsson H., Bake B.S., Jónsdótdr I., Fry L. Psoriasis: A disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol. Today. 1986;7:256–259. doi: 10.1016/0167-5699(86)90005-8. - DOI - PubMed
    1. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., Menter A., Lowe N.J., Krueger G.G., Brown M.J., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Investig. 1999;103:1243–1252. doi: 10.1172/JCI5857. - DOI - PMC - PubMed
    1. Kim J., Krueger J.G. The immunopathogenesis of psoriasis. Dermatol. Clin. 2015;33:13–23. doi: 10.1016/j.det.2014.09.002. - DOI - PubMed
    1. Lowes M.A., Suarez-Farinas M., Krueger J.G. Immunology of psoriasis. Annu. Rev. Immunol. 2014;32:227–255. doi: 10.1146/annurev-immunol-032713-120225. - DOI - PMC - PubMed

LinkOut - more resources